Skip to Content
Merck
  • Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.

Supermolecular inclusion of piroxicam with beta-cyclodextrin: a review of its pharmacological properties in laboratory animals.

European journal of rheumatology and inflammation (1993-01-01)
R E Lister, D Acerbi, S Cadel
ABSTRACT

Piroxicam-beta-cyclodextrin is a novel NSAID; it is a supermolecular inclusion complex designed to improve the risk:benefit ratio of piroxicam. In animal studies it has been shown to be as effective as piroxicam as an anti-inflammatory and analgesic agent but with a more rapid onset of action and reduced gastropathic effects.

MATERIALS
Product Number
Brand
Product Description

USP
Piroxicam, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Piroxicam, meets USP testing specifications
Sigma-Aldrich
Piroxicam, ≥98% (TLC)
Piroxicam, European Pharmacopoeia (EP) Reference Standard
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard